Xenetic Biosciences is trading 5.29% up in pre-market at $3.78 following a recent biotechnology-sector rally; no fresh company-specific announcement was identified for August 24, 2026.
- The stock closed at $3.59 on August 21, 2026.
- Its latest filing and earnings release, dated August 7, 2026, included second-quarter results and continued progress on its DNase platform.
- Recent biotech strength followed positive late-stage data from Moderna and Merck, though that announcement predates the current pre-market move.